Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood

Schizophrenia Research

Volumn 85, Issue 1-3, 2006, Pages 222-231

  Saeedi, Huma ^a   Remington, Gary ^a,b   Christensen, Bruce K ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotics; Cognition; Haloperidol; Healthy volunteer; Mood; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL;

ADULT; ANGER; ARTICLE; CLINICAL TRIAL; COGNITION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENDOCRINE DISEASE; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; MOOD; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AFFECT; ANTIPSYCHOTIC AGENTS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 33745404437     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.03.033     Document Type: Article

References (49)

1. Abraham G., Paing W.W., Kaminski J., Joseph A., Kohegyi E., and Josiassen R.C. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am. J. Psychiatry 160 (2003) 1618-1620
2. Awad A.G., Hogan T.P., Voruganti L.N., and Heslegrave R.J. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int. Clin. Psychopharmacol. 10 (1995) 123-132
3. Barnes T.R., Braude W.M., and Hill D.J. Acute akathisia after oral droperidol and metoclopramide preoperative medication. Lancet 2 (1982) 48-49
4. Belmaker R., and Wald D. Haloperidol in normals. Br. J. Psychiatry 131 (1977) 222-223
5. Blair J.R., and Spreen O. Predicting premorbid IQ: a revision of the National Adult Reading Test. Clin. Neuropsychol. 3 (1989) 129-136
6. Bond A., and Lader M. The use of analogue scales in rating subjective feelings. Br. J. Med. Psychol. 47 (1974) 211-218
7. Bressan R.A., Costa D.C., Jones H.M., Ell P.J., and Pilowsky L.S. Typical antipsychotic drugs-D (2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr. Res. 56 (2002) 31-36
8. Davis J.M., Gosenfeld L., and Tsai C.C. Maintenance antipsychotic drugs do prevent relapse: a reply to Tobias and MacDonald. Psychol. Bull. 83 (1976) 431-437
9. de Haan L., Lavalaye J., Linzen D., Dingemans P., and Booji J. Subjective experience and striatal dopamine D2 receptor occupancy in patients with recent-onset schizophrenia treated with olanzapine or risperidone. Am. J. Psychiatry 157 (2000) 1019-1020
10. de Haan L., van Bruggen M., Lavalaye J., Booij J., Dingemans P.M., and Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am. J. Psychiatry 160 (2003) 303-309
11. de Haan L., Lavalaye J., van Bruggen M., van Nimwegen L., Booij J., van Amelsvoort T., and Linszen D. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can. J. Psychiatry 49 (2004) 290-296
12. Denham J., and Adamson L. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatr. Scand. 47 (1971) 420-430
13. Denham J., and Adamson L. Long-acting phenothiazines in the prevention of relapse of schizophrenic patients. Can. Psychiatr. Assoc. J. 18 (1973) 235-237
14. de Visser S.J., van der Post J., Pieters M.S.M., Cohen A.F., and van Gerven J.M.A. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br. J. Clin. Pharmacol. 51 (2001) 119-132
15. Diamond R. Drugs and the quality of life: the patient's point of view. J. Clin. Psychiatry 46 (1985) 29-35
16. Dossenbach M., Erol A., el Mahfoud Kessaci M., Shaheen M.O., Sunbol M.M., Boland J., Hodge A., O'Halloran R.A., and Bitter I. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J. Clin. Psychiatry 65 (2004) 312-321
17. Farde L., and Nordstrom A.L. PET examination of central D2 dopamine receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs. Psychopharmacol. Ser. 10 (1993) 94-100
18. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., and Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49 (1992) 538-544
19. Gilmer T.P., Dolder C.R., Lacro J.P., Folsom D.P., Lindamer L., Garcia P., and Jeste D.V. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry 161 (2004) 692-699
20. Halbreich U., Kinon B.J., Gilmore J.A., and Kahn L.S. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28 (2003) 53-67
21. Kane J.M. Extrapyramidal side effects are unacceptable. Eur. Neuropsychopharmacol. 11 (2001) 397-403
22. Kapur S., and Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 (2003) 1081-1090
23. Kapur S., and Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 50 (2001) 873-883
24. Kapur S., Remington G., Jones C., Wilson A., DaSilva J., Houle S., and Zipursky R. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am. J. Psychiatry 153 (1996) 948-950
25. Kapur S., Zipursky R., Roy P., Jones C., Remington G., Reed K., and Houle S. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology 131 (1997) 148-152
26. Kapur S., Zipursky R., Jones C., Remington G., and Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 57 (2000) 514-520
27. Keefe R.S.E., Mohs R.C., Bilder R.M., Harvey P.D., Green M.F., Meltzer H.Y., Gold J.M., and Sano M. Neurocognitive assessment in the CATIE Project schizophrenia trial: development, methodology and rationale. Schizophr. Bull. 29 (2003) 45-55
28. Khot V., DeVane C.L., Korpi E.R., Venable D., Bigelow L.B., Wyatt R.J., and Kirch D.G. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics. J. Clin. Psychopharmacol. 13 (1993) 120-127
29. Kornhuber H.H. Chemistry, physiology and neuropsychology of schizophrenia: towards an earlier diagnosis of schizophrenia I. Arch. Psychiatr. Nervenkr. 233 (1983) 415-422
30. Leucht S., Barnes T.R., Kissling W., Engel R.R., Correll C., and Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am. J. Psychiatry 160 (2003) 1209-1222
31. Lewis R. Should cognitive deficit be a diagnostic criterion for schizophrenia?. J. Psychiatry Neurosci. 29 (2004) 102-113
32. Lidenmayer J.P. The pathophysiology of agitation. J. Clin. Psychiatry 61 (2000) 5-10
33. Lovibond S.H., and Lovibond P.F. Manual for Depression Anxiety and Stress Scales (1995), Psychology Foundation, Sydney
34. McNair D., Lorr M., and Droppleman L. POMS Manual. 2nd ed. (1981), Educational and Industrial Testing Service, San Diego
35. Monnelly E.P., and Ciraulo D.A. Risperidone effects on irritable aggression in posttraumatic stress disorder. J. Clin. Psychopharmacol. 19 (1999) 377-378
36. Morrey L. Personality Assessment Inventory: Professional Manual (1991), Psychological Assessmemt Resources, Odessa
37. Narr K.L., Thompson P.M., Szeszko P., Robinson D., Jang S., Woods R.P., Kim S., Hayashi K.M., Asunction D., Toga A.W., and Bilder R.M. Regional specificity of hippocampal volume reductions in first-episode schizophrenia. NeuroImage 21 (2004) 1563-1575
38. Ohmori T., Ito K., Abekawa T., and Koyama T. Psychotic relapse and maintenance therapy in paranoid schizophrenia: a 15 year follow up. Eur. Arch. Psychiatry Clin. Neurosci. 249 (1999) 73-78
39. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., and Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 56 (1999) 241-247
40. Serretti A., De Ronchi D., Lorenzi C., and Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr. Med. Chem. 11 (2004) 343-358
41. Stahl S.M. Psychopharmacology of Antipsychotics (1999), Martin Dunitz, London
42. Swann A.C. Neuroreceptor mechanisms of aggression and its treatment. J. Clin. Psychiatry 64 (2003) 26-35
43. Tamminga C.A., Buchanan R.W., and Gold J.M. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int. Clin. Psychopharmacol. 13 (1998) 21-26
44. Voruganti L., and Awad A.G. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology 171 (2004) 121-132
45. Voruganti L., and Awad A.G. Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects?. Can. J. Psychiatry 49 (2004) 285-289
46. Voruganti L., Slomka P., Zabel P., Costa G., So A., Mattar A., and Awad A.G. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D (2) binding ratios on SPECT imaging. Neuropsychopharmacology 25 (2001) 642-650
47. Watson D., Clark L.A., and Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J. Pers. Soc. Psychol. 54 (1988) 1063-1070
48. Wechsler D. Manual for the Wechsler Adult Intelligence Scale. third edition (1997), Psychological Corporation, San Antonio
49. Yen Y.C., Lung F.W., and Chong M.Y. Adverse effects of risperidone and haloperidol treatment in schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry 28 (2004) 285-290